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ABSTRACT Plasmodium parasites rely heavily on glycolysis for ATP production and
for precursors for essential anabolic pathways, such as the methylerythritol phos-
phate (MEP) pathway. Here, we show that mutations in the Plasmodium falciparum
glycolytic enzyme, phosphofructokinase (PfPFK9), are associated with in vitro resis-
tance to a primary sulfonamide glycoside (PS-3). Flux through the upper glycolysis
pathway was significantly reduced in PS-3-resistant parasites, which was associated
with reduced ATP levels but increased flux into the pentose phosphate pathway.
PS-3 may directly or indirectly target enzymes in these pathways, as PS-3-treated
parasites had elevated levels of glycolytic and tricarboxylic acid (TCA) cycle interme-
diates. PS-3 resistance also led to reduced MEP pathway intermediates, and PS-3-
resistant parasites were hypersensitive to the MEP pathway inhibitor, fosmidomycin.
Overall, this study suggests that PS-3 disrupts core pathways in central carbon me-
tabolism, which is compensated for by mutations in PfPFK9, highlighting a novel
metabolic drug resistance mechanism in P. falciparum.
IMPORTANCE Malaria, caused by Plasmodium parasites, continues to be a devastat-
ing global health issue, causing 405,000 deaths and 228 million cases in 2018. Under-
standing key metabolic processes in malaria parasites is critical to the development of
new drugs to combat this major infectious disease. The Plasmodium glycolytic pathway
is essential to the malaria parasite, providing energy for growth and replication and sup-
plying important biomolecules for other essential Plasmodium anabolic pathways. De-
spite this overreliance on glycolysis, no current drugs target glycolysis, and there is a
paucity of information on critical glycolysis targets. Our work addresses this unmet need,
providing new mechanistic insights into this key pathway.
KEYWORDS Plasmodium falciparum, drug resistance mechanisms, drug targets,
glycolysis, metabolic regulation
The parasite Plasmodium falciparum is the major cause of malaria-associated mor-tality, with an estimated 405,000 deaths reported in 2018 (1). Unfortunately, there
is no broadly effective malaria vaccine, and increasing resistance to current antimalar-
ials is driving the search for new targets for antimalarial drug development (1, 2). The
malaria parasite has a complex life cycle, with the asexual intraerythrocytic stage being
the cause of the clinical manifestations associated with this disease. During this stage,
Citation Fisher GM, Cobbold SA, Jezewski A,
Carpenter EF, Arnold M, Cowell AN, Tjhin ET,
Saliba KJ, Skinner-Adams TS, Lee MCS, Odom
John A, Winzeler EA, McConville MJ, Poulsen
S-A, Andrews KT. 2020. The key glycolytic
enzyme phosphofructokinase is involved in
resistance to antiplasmodial glycosides. mBio
11:e02842-20. https://doi.org/10.1128/mBio
.02842-20.
Editor Thomas E. Wellems, National Institute of
Allergy and Infectious Diseases
Copyright © 2020 Fisher et al. This is an open-
access article distributed under the terms of
the Creative Commons Attribution 4.0
International license.
Address correspondence to Katherine T.
Andrews, k.andrews@griffith.edu.au.
This article is a direct contribution from
Elizabeth A. Winzeler, a Fellow of the American
Academy of Microbiology, who arranged for
and secured reviews by Tania de Koning-Ward,
Deakin University, and Sean Prigge, Johns
Hopkins Bloomberg School of Public Health.
Received 8 October 2020
Accepted 23 October 2020
Published
RESEARCH ARTICLE
Molecular Biology and Physiology
crossm















































the malaria parasite relies heavily on glycolysis for ATP energy production, with glucose
consumption increasing 100-fold in P. falciparum-infected erythrocytes (3). The first
rate-limiting and regulatory step in the glycolytic pathway is the conversion of fructose-
6-phosphate to fructose-1,6-biphosphate (FBP) by the enzyme phosphofructokinase
(PFK). The P. falciparum genome contains two ATP-dependent PFK genes, Pfpfk9 and
Pfpfk11. Pfpfk9 (PF3D7_0915400; chromosome 9 [4]) encodes a 160-kDa protein con-
taining fused  and  domains that is structurally similar to plant PFKs and has low
amino acid similarity to human PFKs (15%) (5). Pfpfk9 has been shown to encode a
catalytically active PFK enzyme (5) and appears to be essential (6). In contrast, Pfpfk11
(PF3D7_1128300; chromosome 11 [4]) appears to be dispensable in asexual-stage P.
falciparum (6).
In recent work, PfPFK9 mutations have been associated with the reversal of fos-
midomycin resistance in P. falciparum (7). Fosmidomycin, an antibiotic and antimalarial
drug candidate, acts as a competitive inhibitor of a key enzyme in methylerythritol
phosphate (MEP) pathway isoprenoid biosynthesis in the apicoplast of the malaria
parasite (8). Fosmidomycin resistance has been linked to the functional loss of haloacid
dehalogenase 1 (PfHAD1), a sugar phosphatase (9). In fosmidomycin-resistant parasites,
loss of PfHAD1 function results in dysregulation of glycolysis and increased flux of
triose-phosphates into the MEP pathway, with a concomitant reduction in the effec-
tiveness of fosmidomycin (9). A second HAD family member, PfHAD2, has also been
implicated in fosmidomycin resistance (7). Curiously, fosmidomycin sensitivity is re-
stored in PfHAD2 mutants that have been subjected to prolonged culture in the
absence of drug pressure. These PfHAD2 mutants gain mutations in PfPFK9 that result
in the restoration of fosmidomycin sensitivity (7).
In this study, we provide the first report that PfPFK9 mutations are associated with
resistance to an antiplasmodial compound. Previously, we screened a panel of primary
sulfonamide glycosides for in vitro growth inhibitory activity against asexual intraeryth-
rocytic stages of drug-sensitive (3D7) and multidrug-resistant (Dd2) P. falciparum
parasites. The most potent sulfonamide glycoside (PS-3) exhibited a 50% inhibitory
concentration (IC50) value of 1 M and 40-fold selectivity for P. falciparum versus
that for mammalian cells (Fig. 1) (10). In this study, P. falciparum parasites were selected
for in vitro resistance to PS-3 (10), followed by whole-genome sequence analysis of
clones to identify putative PS-3 targets and/or resistance mechanisms. A point mutation
in the PfPFK9 gene was shown to be linked to PS-3 resistance and subsequently
confirmed via reverse genetics. While PS-3 did not significantly inhibit recombinant
Plasmodium PFK activity, PS-3-resistant P. falciparum parasites with PfPFK9 gene mu-
tations redirected glucose flux into the pentose phosphate pathway, at the expense of
upper glycolysis, while still maintaining lower glycolysis and continued ATP production.
While the precise target of PS-3 remains undefined, these data suggest that the
FIG 1 PS-3 structure and activity. The thioglucosyl moiety (S or sulfur at the anomeric position) of PS-3
is shown in green, and the primary sulfonamide in light blue. PS-3 contains an acetylated glucose group
joined to a benzene sulfonamide via a triazole linker (dark blue). P. falciparum 3D7/Dd2 and neonatal
foreskin fibroblast (NFF) IC50 values are as previously reported (10).
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redirection of carbon fluxes into the pentose phosphate pathway, mediated by muta-
tions to PfPFK9, confers resistance to this novel antiplasmodial compound.
RESULTS
Generation of PS-3-resistant P. falciparum clones. A P. falciparum 3D7 clone was
generated by limiting dilution (termed 3D7-C3) and used to generate PS-3-resistant
parasites using a stepwise selection method, beginning at 1 IC50 (1 M). After 80
asexual intraerythrocytic cycles, parasites were selected with the ability to grow in
10 the P. falciparum 3D7 wild-type PS-3 IC50 (10 M; termed 3D7-C3PS3) (Fig. 2A).
In contrast, there was no significant difference in IC50 values for the control drug
chloroquine (P  0.05) (Fig. 2B). The 3D7-C3PS3 line remained resistant to PS-3 following
cryopreservation, thawing, and reculture (see Fig. S1A in the supplemental material),
and this phenotype was stable after removal of PS-3 selection pressure for 10 weeks
(Fig. S1B). Exposure of 3D7-C3PS3 parasites to higher concentrations of PS-3 (20 IC50
FIG 2 In vitro profiles of P. falciparum PS-3 resistant parasites, subclones, and PfPFK mutants. The
sensitivity of P. falciparum 3D7-C3PS3 versus that of wild type clone 3D7-C3 was assessed against
compound PS-3 (A) and chloroquine (B). The sensitivity of P. falciparum 3D7-C3PS3 subclones (3D7-
C3PS3-1, 3D7-C3PS3-2, and 3D7-C3PS3-3) and 3D7-C3 was assessed against PS-3 (C) and chloroquine (D).
The sensitivity of P. falciparum PFK9 mutant lines R860G/R860 silent (E) and L513Q/L513 silent (F) was
assessed against PS-3. In each case, the mean percent inhibition ( standard deviation [SD]) compared
to that for DMSO controls was determined using 72-h [3H]hypoxanthine growth inhibition assays for at
least three independent assays, each carried out in triplicate wells. Mean (SD) 50% inhibitory
concentrations (IC50s) were determined using nonlinear regression analysis in GraphPad prism.
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[20 M]) for 8 weeks did not result in a significant alteration in the IC50 (P  0.05)
compared to that for 3D7-C3PS3 selected with 10 PS-3 (see Fig. S2). A comparison of
in vitro IC50 values for 3D7-C3PS3 versus those for 3D7-C3 wild-type parasites showed
generally no significant difference for the clinically used antimalarial drugs chloroquine,
pyrimethamine, cycloguanil, artesunate, atovaquone, and quinine (P  0.05) (Table 1).
Likewise, there was no significant difference in IC50 values for the clinical candidates
KAE609 (11) (PfATP4 inhibitor) and DSM161 (12) (an analogue of DSM265, a dihydro-
orotate reductase [DHOD] inhibitor [13]). This is reflected in the calculated resistance
indices (Ri), which range from 0.8 to 1.6. In contrast, a Ri of 8.3 was obtained when
comparing P. falciparum 3D7-C3 and 3D7-C3PS3 PS-3 IC50 values (Table 1).
Structure-activity relationship analysis of the P. falciparum PS-3 resistance
phenotype. To define which PS-3 structural group(s) contributes to the 3D7-C3PS3
resistance phenotype, PS-3 analogues were tested in in vitro growth inhibition assays
against 3D7-C3 and 3D7-C3PS3 parasites. Compounds included PS-3=, which lacks the
primary sulfonamide (PS) moiety, and four compounds that retain the PS moiety (PS-1,
PS-3, PS-7, and PS-10) (Table 2). All compounds contain a per-O-acetylated glucose type
sugar with an acetyl R group and a triazole substituent (Y  I or H) but vary with respect
to their glycosidic linkage (X  S, O, or SO2) (Table 2). Compared to PS-3, the absence
of the PS moiety in PS-3= resulted in a significant reduction in activity for both
3D7-C3PS3 and 3D7-C3 wild-type parasites (4-fold higher IC50s; P  0.05) (Table 2);
however, the PS-3= Ri remained similar (Ri, 6) (Table 2) to that for the PS-3 selection
compound, indicating that the PS-3 resistance phenotype is independent of the PS
group. Likewise, PS-7 and PS-10 showed a reduction in overall activity against both
3D7-C3PS3 and wild-type 3D7-C3 but retained similar Ri values to that for PS-3 (Ri 6
to 7) (Table 2), indicating that the variable glycosidic linkage (X  S, O, or SO2) (Table 2)
does not impact resistance to PS-3. PS-1, which is identical to PS-3 (Table 2) (Y  I)
except for the triazole substituent (Table 2) (Y  H) showed 2.3-fold reduced activity
against 3D7-C3PS3 versus that against 3D7-C3, suggesting that the iodo substituent
(Y  I) of the triazole moiety is likely also not contributing to the resistance phenotype
of 3D7-C3PS3 parasites. Overall, these structure-activity relationship (SAR) data implicate
the glucose moiety in PS-3 as being associated with the resistance phenotype of
3D7-C3PS3 parasites.
To determine if sugars other than glucose play a role in the 3D7-C3PS3 resistance
phenotype, PS-3 analogues differing only with respect to the sugar group were tested
against 3D7-C3PS3 and 3D7-C3. 3D7-C3PS3 was found to be cross resistant to PS-11
(galactose replacing glucose) and PS-12 (glucuronic acid replacing glucose), as shown
by similar Ri values to that for PS-3 (Table 2). To a lesser extent, 3D7-C3PS3 was found
to be cross resistant to PS-14 (the disaccharide maltose replacing glucose; Ri, 2.5)




Rib P valuec3D7-C3 wild type 3D7-C3PS3
PS-3 1.250 (0.640) 10.410 (1.380) 8.3 0.0006
Chloroquine 0.014 (0.003) 0.011 (0.004) 0.8 0.9142
Pyrimethamine 0.033 (0.010) 0.054 (0.028) 1.6 0.2826
Artesunate 0.004 (0.002) 0.004 (0.001) 1.0 0.6779
DSM161 0.345 (0.065) 0.359 (0.027) 1.0 0.7535
KAE609 0.0015 (0.0001) 0.0014 (0.0003) 0.9 0.5734
Atovaquone 0.0002 (0.0001) 0.0002 (0.0001) 1.0 0.5185
Cycloguanil 0.0103 (0.0004) 0.0141 (0.0002) 1.4 0.0001
Quinine 0.0224 (0.0013) 0.0133 (0.0003) 0.6 0.0101
aMean IC50 ( SD) for three independent experiments, each in triplicate wells.
bRi, resistance index: IC50 resistant line (3D7-C3PS3)/IC50 wild-type line (3D7-C3). The higher the Ri the, higher
the level of resistance.
cStatistical difference between IC50s was determined using an unpaired t test with GraphPad Prism data
analysis software.
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(Table 2). Together, these SAR data suggest that the mode of action of PS analogues
containing the sugars glucose, galactose, glucuronic acid, and, to a lesser extent,
maltose may be affected by the phenotypic change associated with the 3D7-C3PS3
resistance. These sugars have subtle structural and stereochemical differences. Inter-
estingly, 3D7-PfHK, a parasite line that was previously shown to be resistant to the
glucose analogue 2-deoxyglucose (14), is not resistant to PS-3 (data not shown).
Whole-genome sequencing of 3D7-C3PS3 subclones identifies two independent
single nucleotide polymorphisms in the P. falciparum phosphofructokinase (Pf-
PFK) gene. Three independent 3D7-C3PS3 subclones were generated (termed 3D7-
C3PS3-1, 3D7-C3PS3-2, and 3D7-C3PS3-3), and their PS-3 resistance profiles were confirmed
(Fig. 2C). The IC50 values of all the clones were significantly different from that of the
wild-type 3D7-C3 parasites (Fig. 2C) (P  0.05) but not for the control drug chloroquine
(P  0.05) (Fig. 2D). PS-3 resistance indices of 15.0, 6.6, and 10.8 were observed for
3D7-C3PS3-1, 3D7-C3PS3-2, and 3D7-C3PS3-3, respectively. A comparison of the genome
sequences of the three clones versus that for 3D7-C3 revealed 12 new coding muta-
tions, which included two point mutations (L513Q and R860G) in the PfPFK9 gene
(PF3D7_0915400) (Fig. 3; Table S1). The L513Q mutation was found only in clone
3D7-C3PS3-2 and maps to the -domain of PfPK9 (amino acids 1 to 660) (Fig. 3). The
R860G mutation was found in clones 3D7-C3PS3-1 and 3D7-C3PS3-3 and maps to the
-domain (amino acids 777 to 1418) (Fig. 3). Mutations were observed in the P.
falciparum multidrug-resistant protein 2 (PfMDR2; Pf3D7_1447900) and the P. falci-
parum sodium/hydrogen exchanger (PfNHE; Pf3D7_1303500) for the 3D7-C3PS3-1 and
3D7-C3PS3-3 clones (Table S1). The likelihood of finding three independent missense
mutations in PfPK9 by chance is very low (P  1.7e	10, hypergeometric mean
function). Furthermore, in contrast to that for PfMDR2, no PfPK9 mutations were
detected in a systematic analysis of the genome sequences of 262 evolved parasites
resistant to 37 diverse compounds (15) performed with the same sequence analysis
pipeline. No other common gene amplifications were observed in the three indepen-
dent clones analyzed.
TABLE 2 In vitro activity of PS glycoside analogues against P. falciparum 3D7-C3PS3 and
3D7-C3 parasites
Compound PS present
Structural featurea IC50 (M)b
Ric P valuedSugar R Y X 3D7-C3 3D7-C3PS3
PS-3 Yes Glucose Ac I S 1.25 (0.64) 10.41 (1.38) 8.3 0.0006
PS-3= No Glucose Ac I S 6.42 (1.43) 38.73 (2.40) 6.0 0.0003
PS-7 Yes Glucose Ac I SO2 9.08 (2.70) 65.53 (4.90) 7.2 0.0351
PS-10 Yes Glucose Ac I O 5.15 (1.42) 31.56 (18.53) 6.1 0.1420
PS-11 Yes Gal Ac I S 5.03 (2.50) 22.40 (7.90) 4.5 0.0219
PS-12 Yes GlcOMe Ac I S 4.13 (2.36) 19.62 (6.95) 4.8 0.0217
PS-15 Yes Mal Ac I S 3.14 (0.97) 7.83 (0.85) 2.5 0.0032
PS-1 Yes Glucose Ac H S 43.19 (9.04) 100.00 2.3 ND
aGal, galactose; GlcOMe, glucuronic acid; Mal, maltose; Ac, acetate; H, hydrogen; I, iodine; S, sulfur; SO2,
sulfur dioxide; O, oxygen.
bMean IC50  SD for three independent experiments each in triplicate wells.
cRi, resistance index: IC50 resistant line (3D7-C3PS3)/IC50 wild-type line (3D7-C3). The higher the Ri, the higher
the level of resistance.
dStatistical difference between IC50s was determined using an unpaired t test with GraphPad Prism data
analysis software.
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Modeling of glycoside resistance alleles. To inform the possible structural basis of
compound resistance, we evaluated the effects of resistance alleles (R860G and L513Q)
on three-dimensional models of PfPFK9  and  domains (Fig. 3). Currently, no structure
exists for the distinct “long” PFKs observed in apicomplexans. Our structural model
shows that the R860G and L513Q mutations do not share cognate regions of their
respective domains. The R860G mutation is adjacent to the substrate-binding pocket of
the C-terminal  domain, while the L513Q mutation is buried between an alpha-helix
and beta-strand of the N-terminal  domain and is not predicted to impact substrate-
binding or catalytic residues. This suggests that these mutations may share their
resistance phenotype through a more general mechanism of overall reduced PFK
function rather than a specific change in a particular inhibitor-protein binding interface.
PfPFK9 R860G mutation validated as a resistance mechanism of PS-3. CRISPR/
Cas9-based genome editing was used to validate the contribution of the two PfPFK9
mutations, L513Q and R860G, to the resistance phenotype. Donor templates were
synthesized and cloned into a CRISPR vector encoding Cas9 and one of two single
guide RNAs (sgRNAs) targeting the relevant locus (see Fig. S3). For each mutation, two
donor templates were generated encoding either the putative resistance mutation
(e.g., L513Q) or a silent control (e.g., L513L). Additional silent mutations common to
both sets of donors were also included to prevent sgRNA binding to the repair locus
(Fig. S3). The mutations were introduced into the Dd2 strain, and clonal lines were
derived. The R860G-edited line demonstrated a 2.1-fold increase in IC50 values com-
pared to that for the R860 silent control (P  0.0001) (Fig. 2E). There was no significant
change in IC50 values for the L513Q-edited line compared to that for the L513 silent
control (P  0.05) (Fig. 2F), which may possibly be due to the different genetic
background (Dd2 versus 3D7) or the contribution of additional alleles. These data,
nevertheless, provide evidence of an association between the PfPFK9 R860G mutation
and P. falciparum resistance to PS-3.
Mutations in PfPFK9 lead to changes in central carbon metabolic flux. To
investigate the impact of nonsynonymous mutations in PfPFK on parasite metabolism,
13C-glucose labeling studies were undertaken on 3D7-C3PS3-1 and 3D7-C3PS3-3 (both
FIG 3 Mutations in 3D7-C3PS3 clones map to the  and  domains of PfPFK9 (PF3D7_0915400). The
glycoside-resistance allele L513Q (clone 3D7-C3PS3-2) maps to the -domain and the R860G allele (clones
3D7-C3PS3-1 and 3D7-C3PS3-3) maps to the -domain of PfPFK9. (Top) Three-dimensional structural model
of PfPFK9, with wild-type residues in blue and predicted position of variant residues indicated in red.
Products fructose 1,6-bisphosphate (FBP) and ADP (ADP) are shown as stick figures with a color scheme
(carbon, white; nitrogen, blue; oxygen, red; phosphate, orange; hydrogen, not displayed). (Bottom)
Domain structure of PfPFK9, with positions of resistant variants indicated in red.
Fisher et al. ®














































containing the R860G mutation). Erythrocytes infected with trophozoite-stage parasites
were labeled with 13C-glucose (present in medium at a 1:1 ratio with 12C-glucose) for
30 min, and incorporation into a wide range of intermediates in central carbon
metabolism was quantitated by liquid chromatography-mass spectrometry (LC-MS).
The pool sizes of several glycolytic intermediates immediately downstream of PfPFK,
including fructose-1,6-bisphosphate and dihydroxyacetone phosphate (DHAP), were
significantly reduced in the mutant lines, whereas those of several nucleoside mono-
and diphosphates were elevated (Fig. 4A). The level of 13C enrichment in these
downstream intermediates was also greatly reduced, suggesting that the metabolic flux
through PFK was severely compromised in 3D7-C3PS3-1- and 3D7-C3PS3-3-infected
erythrocytes (Fig. 4B). Reduced flux through the reversible aldolase reaction was further
supported by the markedly reduced levels of 3-labeled fructose-1,6-bisphosphate in
the mutant lines, which reflects the rate of interconversion of DHAP/glyceraldehyde-
3-phosphate (GAP) and fructose-1,6-bisphosphate. These labeling studies indicate that
mutations acquired in 3D7-C3PS3-1 and 3D7-C3PS3-3 parasites lead to reduced PfPFK
activity. Interestingly, 13C enrichment in GAP, an intermediate in both glycolysis and the
pentose phosphate pathway (PPP), was unaltered in 3D7-C3PS3-1 and 3D7-C3PS3-3
parasites, while labeling of several intermediates in the oxidative and nonoxidative PPP
(sedoheptulose-7-P and ribose-5-P) was increased in these mutant lines. These data
strongly suggest that partial loss of PfPFK activity leads to rerouting of carbon flux
through the PPP, leading to the production of GAP that can still be catabolized in lower
glycolysis. This bypass would allow ATP-producing steps in lower glycolysis to proceed,
albeit at a reduced rate, as evidenced by the lower levels of synthesis of phosphoe-
nolpyruvate (PEP) and lactate (Fig. 4B). The reduction of glycolytic flux in 3D7-C3PS3-1
and 3D7-C3PS3-3 was consistent with an approximate 25% reduction in extracellular
lactate secretion (Fig. 4B). The rerouting of carbon flux through the PPP, at the expense
of glycolysis, would be expected to come with a fitness disadvantage as a result of
reduced ATP production. This hypothesis was supported by the significant increase in
ADP and AMP levels in the mutant lines, leading to reduced ATP/ADP and ATP/AMP
ratios (Fig. 4A). Glycolysis is also the source of precursors for a number of anabolic
pathways, such as isoprenoid biosynthesis, which uses phosphoenolpyruvate and
DHAP generated downstream of PFK. Lastly, the isoprenoid biosynthetic intermediates
deoxyribose-1-phosphate (DOXP) and methylerythritol-cyclo-pyrophosphate (MEcPP)
were significantly reduced in both 3D7-C3PS3-1 and 3D7-C3PS3-3, indicating reduced flux
into this pathway and an additional fitness disadvantage to PFK mutations (Fig. 4C).
3D7-C3PS3 subclones display slowed in vitro growth compared to that of
wild-type 3D7-C3 parasites. To assess in vitro growth dynamics of PS-3-resistant
parasites, the in vitro growth profiles of 3D7-C3PS3-1 and 3D7-C3PS3-3, compared to that
of wild-type 3D7-C3 parasites, were examined by comparing growth over 72 h com-
mencing at 3 to 6 h postinvasion (see Fig. S4). No significant difference in parasitemia
was seen up to 30 h postinvasion for 3D7-C3PS3-1 and 3D7-C3PS3-3 compared to that for
3D7-C3. In contrast, at 51 to 54 h and 75 to 78 h postinvasion, a 2-fold reduction in
total parasitemia was observed for both 3D7-C3PS3 subclones compared to that of the
wild type (P  0.05 and P  0.01, respectively) (Fig. S4). Upon examination of each
developmental stage, no significant difference was seen in the percentages of each
stage (early rings, mid/late rings, early/mid trophozoites, late trophozoites/early schi-
zonts, and late schizonts) up to 30 h postinvasion for 3D7-C3 versus those for 3D7-
C3PS3-1 and 3D7-C3PS3-3 (P  0.05) (see Fig. S5A and B). However, at 51 to 54 h
postinvasion, 2-fold reductions were seen in the percentages of rings for 3D7-C3PS3-1
and early/mid trophozoites for 3D7-C3PS3-3 compared to those for 3D7-C3 (P  0.05)
(Fig. S5C). Additionally, at 72 to 78 h postinvasion, a 2-fold increase in the percentage
of late trophozoite/early schizonts and a 5-fold decrease in the percentage of late
schizonts was observed for both 3D7-C3PS3 subclones compared to those for the wild
type (P  0.01 and P  0.05, respectively) (Fig. S5D). Overall, these data suggest that
parasite growth is developmentally delayed in 3D7-C3PS3-1 and 3D7-C3PS3-3 parasites.
Phosphofructokinase in Glycoside Resistance ®














































FIG 4 Dynamic 13C-U-glucose labeling of PS-3-sensitive and -resistant trophozoite-stage P. falciparum-infected erythrocytes. Purified
(95%) trophozoite-stage P. falciparum-infected erythrocytes were incubated in RPMI 1640 medium containing a 1:1 mixture of 12C/13C6-
glucose (11 mM) and collected for LC-MS analysis across a 30-min time course. (A) Total metabolite pools were monitored over the time
course and are expressed as the log2 ratio of the 3D7-C3PS3-1 or 3D7-C3PS3-3 to the wild-type parental strain. (B) The rate of 13C incorporation
into glycolytic and pentose phosphate pathway intermediates. The y axis represents the amount of fully labeled metabolite as the estimated
intracellular concentration (with the exception of fructose-1,6-Bisphosphate which depicts both the forward [M  6], and backward [M  3]
species). The data presented in panels A and B represent the averages from three biological replicates ( standard errors of the means
[SEMs]) and the excreted lactate data from two biological replicates (SDs). (C) The intracellular pool of the isoprenoid biosynthetic
intermediates in wild-type (WT) and 3D7-C3PS3-1 or 3D7-C3PS3-3 purified infected erythrocytes. The total pool sizes of deoxyribose-1-
phosphate (DOXP), methylerythritol-cyclo-pyrophosphate (MEcPP), and isopentyl-pyrophosphate (IPP) are presented as arbitrary ion counts
(normalized for data acquisition and degradation across different days), and represent three biological replicates performed on different
days (means  SEMs). One-way analysis of variance (ANOVA) testing was performed to test statistical significance. *, P  0.05.
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Metabolite profiling of 3D7-infected red blood cells treated with PS-3. To
investigate whether PfPFK is a direct target of PS-3 or if mutations in PfPFK provide a
metabolic bypass that indirectly confers resistance, erythrocytes infected with purified
trophozoite-stage P. falciparum 3D7 were treated with PS-3 (40 M; equivalent to 4
IC50 for this parasite life cycle stage at 48 h of exposure) for 2 h, and changes in
metabolite levels determined using untargeted LC-MS profiling (Fig. 5). More than 90
of the 3,327 detected mass-to-charge (m/z) features were significantly different (P 
0.05, false-discovery rate [FDR] corrected) between those treated with PS-3 and the
untreated control. The METLIN database was queried for possible identities using the
M-H criteria with a mass tolerance of 10 ppm (assuming that metabolites existing as
other adducts will also be present as the M-H adduct). Several features corresponded
to glycolytic intermediates, and these were subsequently verified using authentic
standards (Fig. 5, highlighted in yellow). In particular, lactate and pyruvate were
significantly increased following PS-3 treatment, with glycerate and the tricarboxylic
acid (TCA) cycle-linked intermediates 2-oxoglutarate and 2-hydroxyglutarate also sig-
nificantly elevated. This metabolic phenotype is distinct from that observed in the
PS-3-resistant lines, indicating that PS-3 does not directly target PFK but inhibits other
steps in central carbon metabolism that are compensated for by rerouting of glucose
into the pentose phosphate pathway and/or reduced flux in lower glycolysis.
Antiplasmodial glycosides do not directly inhibit apicomplexan phosphofruc-
tokinases. To further evaluate whether PfPFK9 represents the direct target of antiplas-
modial glycosides, we evaluated compound sensitivity against P. falciparum and Plas-
modium knowlesi PFK9. While we, and others, have not been able to purify full-length
PfPFK9 (5), P. falciparum and P. knowlesi / domains readily express as active individual
domains (see Fig. S6). We screened each recombinant protein for enzymatic inhibition
at a single compound concentration (50 M) (Fig. 6A), revealing possible modest
inhibition of purified PfPFK by compounds PS-3 and PS-12. However, dose-responsive
inhibition of PfPFK confirmed little to no enzymatic inhibition by these compounds at
concentrations similar to the compound’s cellular inhibition values (biochemical IC50s
as follows: PS-3, 22  4.33 M; PS-12, 21  1.49 M) (Fig. 6B). The lack of direct
inhibition of any domain of these PfPFK enzymes suggest PfPFK9 may not be the direct
target of PS-3.
FIG 5 Metabolite perturbations following exposure to PS-3. Untargeted metabolite profiling of purified
trophozoite-stage parasite-infected erythrocytes treated with 40 M PS-3 (2 h). Mass-to-charge (m/z)
features were aligned and a pairwise comparison performed between PS-3-treated and untreated
purified infected erythrocytes using a P value of 0.05 (FDR corrected) and fold change of 2 cutoffs for
determining significant peaks. Data are presented as the mean ratios from four independent replicates.
Putative metabolite identifications were made via the METLIN database and confirmed with authentic
standards (highlighted yellow).
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PfPFK mutants are not resistant to Plasmodium lactate transporter inhibitors.
The increases observed in the lower glycolytic intermediates lactate, pyruvate, and
glycerate in PS-3-treated trophozoites raised the possibility that PS-3 may act by
blocking lactate efflux across the parasite plasma membrane. The Plasmodium formate
nitrite transporter (PfFNT) mediates the efflux of lactate from the malaria parasite (16,
17), and two malaria box compounds (MMV007839 and MMV000972) were recently shown
to inhibit lactate transport via inhibition of PfFNT (18). To further investigate if PS-3
targeting is related to PfFNT inhibition, the PfPFK R860G and L513Q mutant parasites were
screened against MMV007839 and MMV000972 in 72-h growth inhibition assays. No
significant difference (P  0.05) was observed in IC50 values for each compound against
both the mutant and silent control lines (MMV 007839: R860G IC50, 0.13  0.01 M; R860
silent IC50, 0.15  0.02 M; MMV 000972: R860G IC50, 0.76  0.08 M; R860 silent IC50,
0.81  0.12 M; MMV 007839: L513Q IC50, 0.13  0.06 M; L513 silent IC50, 0.15  0.03 M;
MMV 000972: L513Q IC50, 0.59  0.27 M; L513 silent IC50, 0.93  0.16 M) (see Fig. S7).
This lack of cross-resistance suggests that PS-3 may not target PfFNT.
PS-3-resistant clones are hypersensitive to fosmidomycin. Our metabolomic
studies indicated that glycolytic flux is reduced in 3D7-C3PS3 subclones, which leads to
decreased flux of glycolytic intermediates into the apicoplast isoprenoid DOXP biosyn-
thetic pathway (Fig. 4C). Previous studies on the PfHAD1 mutants have shown that
changes in glycolytic flux directly impact the resistance of asexual intraerythrocytic-
stage P. falciparum to fosmidomycin (9), a potent competitive inhibitor of the apico-
plast MEP pathway enzyme deoxyxyluose phosphate reductoisomerase (PfDXR) (19).
We therefore assessed whether the observed decrease in glycolytic flux in the PS-3-
resistant lines was associated with increased sensitivity to fosmidomycin in 72-h growth
inhibition assays. A significant increase in activity for fosmidomycin was seen for all
three 3D7-C3PS3 clones compared to that for the 3D7-C3 wild-type parasites (Fig. 7A)
FIG 6 Antiplasmodial glycosides do not inhibit Plasmodium phosphofructokinases. (A) Compounds PS-3,
PS-3=, and PS-12 were screened for activity (at 50 M) against recombinant protein domains PkPFK,
PkPFK, PfPFK, and PfPFK; dotted lines represent maximal activity for each enzyme and minimal
activity from assay background as determined from a catalytically dead PfPFK. (B) Inhibitory dose
response of PfPFK for compounds PS-3 and PS-12.
FIG 7 In vitro profile of P. falciparum PS-3-resistant clones against fosmidomycin. The sensitivity of P.
falciparum 3D7-C3PS3 subclones 3D7-C3PS3-1, 3D7-C3PS3-2, 3D7-C3PS3-3, and 3D7-C3 against compound fos-
midomycin (A) and the control compound PS-3 (B) was assessed using 72-h [3H]hypoxanthine uptake growth
inhibition assays. In each case, 3 independent assays, each in triplicate wells, were carried out, and 50%
inhibitory concentrations (IC50) were determined using nonlinear regression analysis in GraphPad prism.
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(8-fold higher IC50 values; P  0.01 [3D7-C3PS3-1 and 3D7-C3PS3-2], P  0.05 [3D7-
C3PS3-2]). As previously observed (Fig. 2C), PS-3 showed a significant decrease in activity
for all three 3D7-C3PS3 clones compared to the that for 3D7-C3 (Fig. 7B) (7- to 15-fold
lower IC50s; P  0.001). The PS-3-resistant parental line (3D7-C3PS3) also displayed
hypersensitivity to the P. falciparum apicoplast inhibitor clindamycin (see Fig. S8)
(3-fold higher IC50 values for 3D7-C3 compared to that for 3D7-C3PS3; n  2). Collec-
tively, these data support the hypothesis that resistance to PS-3 in the 3D7-C3PS3 clones
is associated with metabolic adaptation that leads to decreased availability of glycolytic
intermediates for anabolic pathways, such as isoprenoid biosynthesis.
Increased glycolytic flux may also result in resistance to PS-3. To further
investigate the mode of action of PS-3 and potential resistance mechanisms, we
investigated the sensitivity of the P. falciparum had1 mutant, AM1, to PS-3. The Pfhad1
gene encodes a haloacid dehalogenase that dephosphorylates a range of glycolytic
intermediates in vitro and appears to be involved in negatively regulating glycolytic
flux. Loss-of-function mutations in Pfhad1 are associated with increased flux of glyco-
lytic intermediates into isoprenoid synthesis and resistance to fosmidomycin (9). The
AM1 parasite line exhibited a 5-fold increase in resistance to PS-3 compared to that of
the parental 3D7 line (P  0.001) (Fig. 8A). This level of resistance is comparable to that
exhibited by the AM1 line to fosmidomycin (i.e., 4-fold increase in IC50; P  0.05)
(Fig. 8B). This finding suggests that global changes in central carbon metabolism that
can be associated with either an increase in glycolytic flux (as occurs in AM1) or a
decrease in glycolytic flux (as occurs in the 3D7-C3PS3 subclones) increase the resistance
of asexual stages to PS-3. However, unlike the control fosmidomycin, the antiplasmo-
dial activity of PS-3 was not rescued by supplementation with isoprenoid isopentenyl
pyrophosphate (IPP) (see Fig. S9). Furthermore, we find that PS-3 does not directly
inhibit PfHAD1 or PfHAD2 enzyme activity in vitro (Fig. 9). Together, these data strongly
show that PS-3 has a distinct mechanism of action from other direct MEP pathway
inhibitors, such as fosmidomycin.
FIG 8 In vitro profile of P. falciparum fosmidomycin-resistant parasites against PS-3. The sensitivity of P.
falciparum Fosr 3D7-AM1 and wild-type 3D7-MR4 against compound PS-3 (A) and fosmidomycin (B) was
assessed using 72-h [3H]hypoxanthine uptake growth inhibition assays. In each case, three independent
assays, each in triplicate wells, were carried out, and 50% inhibitory concentrations (IC50) were deter-
mined using nonlinear regression analysis in GraphPad prism.
FIG 9 Antimalarial glycosides do not inhibit recombinant PfHAD1 and PfHAD2. Inhibitory dose-
responses for antimalarial glycosides against recombinant proteins PfHAD1 (A) and PfHAD2 (B).
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Malaria remains a major global concern with efforts to control this disease being
hampered by parasite drug resistance and the lack of a broadly effective vaccine (1).
Although there are several new chemotherapeutics in various stages of preclinical or
clinical development, most of these have previously exploited targets or are reformu-
lations or different combinations of existing antimalarial drugs (20). Therefore, strate-
gies to identify new antimalarial drug targets and antiplasmodial chemotypes that have
novel modes of action are crucial. Fortunately, recent reductions in the cost of whole-
genome sequencing and the development of comprehensive global metabolomic
profiling approaches have begun to yield some exciting progress in the antimalarial
target identification arena. When combined with the selection of drug-resistant P.
falciparum lines, this approach has resulted in the identification of new antimalarial
targets and resistance mechanisms (11, 21, 22).
In this study, in vitro resistance selection was utilized to generate P. falciparum
parasites resistant to an antiplasmodial glycoside (PS-3) (10). Importantly, PS-3-resistant
parasites displayed no in vitro resistance to several clinically used antimalarial drugs or
to two compounds that represent chemical classes under clinical development (11, 12),
suggesting a novel mode of action/resistance. Historically, the PS moiety is known to
inhibit carbonic anhydrase (CA) enzyme activity in many organisms (23), including P.
falciparum (24, 25). In this study, we demonstrate that PS-3 resistance in P. falciparum
is not linked to the PS moiety, as no change in the resistance profile was observed for
PS-3=, the non-PS structural analogue of PS-3 (Table 2). Further screening of PS
glycoside analogues against PS-3-resistant parasites revealed that the glucose compo-
nent of PS-3 may be contributing to the resistance phenotype. These data support
genome sequencing data of 3D7-C3PS3 clones and subsequent validation using reverse
genetics, which indicate that the point mutation (R860G) in PfPFK9, the gene that
encodes an isoform of the glycolytic enzyme phosphofructokinase, contributes to PS-3
resistance. However, the resistance index of the R860G-edited line was lower than that
observed for the 3D7-C3PS3-1 and 3D7-C3PS3-3 clones (Ri, 2.1, 10.8, and 15, respec-
tively). This may be attributed to mutations in the P. falciparum multidrug-resistant
protein 2 (PfMDR2; Pf3D7_1447900) and/or the P. falciparum sodium/hydrogen ex-
changer (PfNHE; Pf3D7_1303500), observed in the 3D7-C3PS3-1 and 3D7-C3PS3-3 clones
only (see Table S1 in the supplemental material). The role of PfMDR2 in antimalarial
drug resistance is unclear, with some weak evidence linking resistance to pyrimeth-
amine (26) and sulfadoxine (27) treatments. Likewise, there are contradictory reports on
the association of sequence polymorphisms in the PfNHE gene and quinine resistance
(28–31). In this study, the 3D7-C3PS3 parasites were not resistant to pyrimethamine and
quinine (Table 1); however, the PfMDR2 and PfNHE mutations observed in the 3D7-
C3PS3-1 and 3D7-C3PS3-3 clones were not reported previously; therefore, further studies
are required to confirm if these mutations are associated with resistance to PS-3. While
mutations in PfMDR2 and PfNHE genes may be contributing to PS-3 resistance, this is
more likely to be via nonspecific multidrug resistance mechanisms (32, 33). On the
other hand, the PFK enzyme has an essential housekeeping role in P. falciparum central
carbon metabolism; therefore, mutations in this gene are more likely to be target
associated. Surprisingly, the L513Q-edited line was not resistant to PS-3, and the
3D7-C3PS3-2 clone containing this mutation did not share any other common mutations
with the other two clones (Table S1). In this case, it is possible that multiple background
mutations (Table S1) are contributing to the resistance profile of the 3D7-C3PS3-2 clone
and masking the effect that the L513Q mutation may be exhibiting. Alternatively, our
modeling suggests that the L513Q mutation may have less of an effect on PfPFK
function due to its more distal proximity to the substrate-binding pocket than the
R860G mutation (Fig. 3). It should also be noted that the L513Q clone reported in this
study is a subclone of the original L513Q clone generated. This original clone did
display resistance to PS-3 (6-fold increase in IC50 [n  1] for two independent PS-3
stocks; data not shown). However, this phenotype was lost following cryopreservation,
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and a reversion to the wild-type genotype was observed. It is therefore conceivable that
the L513Q subclone may have gained mutations in another region of the genome that
may have restored sensitivity to PS-3. Nonetheless, overall, these data strongly suggest
that the PfPFK R860G mutation contributes to PS-3 resistance, suggesting that altera-
tions in glycolytic flux help to bypass the mode of action of PS-3.
To further understand the impact that the R860G PfPFK mutation has on P. falci-
parum metabolism, 13C-glucose fluxes were measured in both the PS-3-resistant clones
(3D7-C3PS3-1 and 3D7-C3PS3-3) and 3D7-C3 wild-type parasites. These studies revealed
a profound rewiring of glucose fluxes in the two resistant clones. In particular, a
reduction in labeling of intermediates immediately downstream of PFK was associated
with increased flux of 13C-glucose into the PPP (Fig. 4). The redirection of glucose-6-
phosphate into the PPP likely accounts for the reduction of ATP/ADP and ATP/AMP
ratios and reduced in vitro growth of PS-3-resistant parasites (Fig. S4). On the other
hand, increased flux into the PPP would allow regeneration of NADPH and contribute
to a more robust redox state. Surprisingly, our data suggest that PfPFK may not be the
direct target of PS-3, as PS-3 was unable to inhibit recombinant PfPFK and P. knowlesi
PFK (PkPFK) enzymes (Fig. 6). Furthermore, in silico homology modeling predicts that
PS-3 is not likely to affect PFK substrate binding or catalysis. Nonetheless, it should be
noted that PS-3 was only tested against the individual subunits of PfPFK, as no
full-length enzyme is available; thus, we cannot completely rule out PfPFK9 as a target
of PS-3. However, PS-3 could in principal inhibit another enzyme in the glycolytic
pathway or in the pentose phosphate pathway. Initially, we hypothesized that PS-3 may
inhibit the parasite’s lactate transporter (P. falciparum formate nitrite transporter, or
PfFNT, a validated drug target [16, 17]), resulting in a toxic buildup of metabolites. This
would be consistent with the increases seen in the lower glycolytic intermediates
(lactate, pyruvate, and glycerate) in PS-3-treated trophozoites (Fig. 10). PS-3-resistant
parasites may overcome this toxicity by redirecting glycolytic flux away from lower
FIG 10 Overview of the central carbon pathways and metabolites associated with PS-3 activity and resistance. Upregu-
lation (1) and downregulation (2) of metabolites observed in PS-3-resistant parasites (red arrows, 13C glucose labeling
studies) and PS-3-treated parasites (green arrows, metabolic profiling of PS-3 treated Pf3D7). PFK, phosphofructokinase.
DHAP, dihydroxyacetone phosphate; GAP, glyceraldehyde-3-phosphate; PEP, phosphoenolpyruvate; DOXP, deoxyribose-
1-phosphate; MEcPP, methylerythritol-cyclo-pyrophosphate; IPP, isopentenyl-pyrophosphate.
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glycolysis, resulting in less lactate being excreted and hence reducing the potency of
PS-3. However, the L513Q and R860G mutant parasites were not cross resistant to the
PfFNT inhibitors MMV000972 and MMV007839 (18) (Fig. S7). Moreover, the elevation of
pyruvate and lactate following PS-3 treatment is consistent with PfFNT inhibition, but
PS-3 treatment does not lead to the additional perturbations reported for PfFNT
inhibition (e.g., pyrimidine biosynthesis and hemoglobin catabolism [18]). However, it
is possible that differences in lactate accumulation may exist between Pf3D7 and PfDd2,
warranting PfFNT inhibition studies against the 3D7 PS-3-selected clones. To the best
of our knowledge, there are no reports comparing 3D7 and Dd2 lactate metabolism,
but we do know that 3D7 lactate metabolic profiles are similar to the profiles of other
multidrug-resistant strains 7G8 and K1 (34) and a Pf3D7 chloroquine-resistant trans-
porter (PfCRT) mutant line (35). Therefore, while we cannot completely discount the
possibility that PS-3 may partially block PfFNT, with the evidence presented, we think
another target is leading to the observed disruptions and eventual cell death. For
example, PS-3 may inhibit an enzyme in the PPP, accounting for the accumulation of
intermediates in glycolysis (glucose-6-P, pyruvate, lactate) and the TCA cycle (2-
oxoglutarate and 2-hydroxyglutarate). In this case, PS-3-resistant parasites may have
adapted by diverting the glycolytic intermediates (fructose-6-phosphate [F6P] and GAP)
into the nonoxidative arm of the pentose phosphate pathway to overcome the effects
of PS-3 (Fig. 10). In P. falciparum, the nonoxidative reactions of the PPP are mainly
designed to produce ribose-5-phosphate (R5P) for nucleic acid synthesis. The nonoxi-
dative arm of the PPP can also utilize the glycolytic intermediates (F6P and GAP) to
produce R5P and vice versa (36). Two key enzymes involved in these processes are
glucose-6-phosphate dehydrogenase 6-phosphogluconolactonase (PfGluPho) (37) and
transketolase (38), both of which have been characterized, are essential for asexual
growth (6, 37), and differ structurally from their human homologues (37, 38), making
them potential drug targets. Finally, it is possible that PS-3 may target other processes
that lead to increased oxidative stress or loss of redox balance, such as mitochondrial
metabolism, which is compensated for by increased flux through the PPP (with
concomitant regeneration of NADPH).
In addition to reduced glycolytic flux, we also observed a reduction in the MEP
pathway metabolites (DOXP, MEcPP, and IPP) in PS-3-resistant parasites (Fig. 10). The
MEP pathway is essential for the synthesis of isoprenoids in P. falciparum (39) and is
dependent on the continuous import of glycolytic intermediates from the cytoplasm
(9). The lead antimalarial drug fosmidomycin targets the MEP pathway enzyme, de-
oxyxylulose phosphate reductoisomerase (DXR), and fosmidomycin resistance has been
linked to mutations in P. falciparum haloacid dehalogenases (PfHAD1/2) (7, 9). While we
found that fosmidomycin-resistant parasites (Fosr AM1 PfHAD1 mutant) were also
resistant to PS-3, the activity of PS-3 was not able to be rescued by IPP (isoprenoid
precursor), and PS-3 did not inhibit Plasmodium HAD1/HAD2 recombinant enzymes.
This suggests that PS-3 has a different mechanism of action/resistance to fosmidomy-
cin. In contrast, PS-3-resistant parasites were found to be hypersensitive to fosmido-
mycin. Given that fosmidomycin targets DXR, it is likely that the reduction in DXR’s
substrate (DOXP) in PS-3-resistant parasites, coupled with a decrease in MEcPP and
IPP, results in an increase in fosmidomycin activity. Increased sensitivity to fosmido-
mycin has also been reported in P. falciparum parasites lacking phosphoglycolate
phosphatase (PGP) (40). PGP, a third member of the P. falciparum HAD family, has
been shown to be involved in regulating glycolysis and PPP flux in asexual P.
falciparum (40). In Δpgp parasites, the loss of PGP leads to the inhibition of the PPP
enzyme 6-phosphogluconate dehydrogenase (6-PGD), resulting in reduced glycolytic
flux and causing reduced isoprenoid biosynthesis and increased sensitivity to fosmido-
mycin (40). Interestingly, fosmidomycin-resistant parasites harboring mutations in Pf-
HAD2 display the opposite metabolomic profile to that of PS-3-resistant parasites. As
mentioned above, PS-3-resistant parasites exhibit decreased levels of the metabolites
FBP, DOXP, and MEcPP, whereas a reported increase in these metabolites is seen in
PfHAD2 mutants (7). In PfHAD2 mutants, the increase in FBP is thought to lead to the
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increase of glycolytic intermediates into the MEP pathway, which results in an increase
of MEP pathway metabolites, thus reducing the sensitivity to fosmidomycin (7). Fur-
thermore, mutations in PfPFK9 have been shown to restore fosmidomycin sensitivity in
these PfHAD2 mutant parasites (7); however, these mutations are not the same as those
seen in PS-3-resistant parasites. Overall, these findings provide further evidence that
PfPFK9 plays an important regulatory role in central carbon metabolism to modify drug
sensitivity.
In this study, we identified a novel mechanism of P. falciparum drug resistance and have
further highlighted the importance of the role of PfPFK9 in regulating central carbon
metabolism to offset the effects of antiplasmodial compounds. While the specific molecular
target of PS-3 remains unclear, it is promising that no cross-resistance exists with several of
our clinically used antimalarials, indicating that this chemical class is likely to have a
different mode of action from that of our current drugs. Furthermore, our PS-3-resistant
parasites will provide a useful tool for studying central carbon metabolism in P. falciparum
and aid in identifying other inhibitors of these pathways for development as antimalarial
drug leads.
MATERIALS AND METHODS
Compounds. PS glycosides and matched control compounds were synthesized as previously re-
ported by us (10). Chloroquine, artesunate, pyrimethamine, and cytochalasin B were purchased from
Sigma-Aldrich, USA. DSM161 (12) was supplied by Margaret Philips from UT Southwestern, Dallas, TX,
USA. Stock solutions were prepared in 100% dimethyl sulfoxide (DMSO; Sigma-Aldrich, USA), stored at
	20°C and diluted as required.
P. falciparum in vitro culture. P. falciparum-infected erythrocytes were cultured in O-positive human
erythrocytes in RPMI 1640 medium (Gibco, USA) containing 10% heat-inactivated pooled human sera
and 5 g/ml gentamicin (Sigma, USA). Cultures were maintained at 37°C in a gas mixture composed of
5% O2, 5% CO2, and 90% N2, as described previously (41).
Cloning of P. falciparum parasites by limiting dilution. P. falciparum-infected erythrocytes were
cultured under standard culture conditions and synchronized to ring stage using sorbitol treatment (42).
Synchronous ring-stage parasites were cultured for two cycles (96 h) on a plate shaker (Gyro mini; Labnet,
USA) under standard culture conditions until multiple infections were less than 1%, as determined by
microscopic examination of Quickdip-stained (POCD, Australia) thin blood films. Following cell counts
with a hemocytometer, cultures were diluted to 0.5 and 0.1 parasites per 200 l (2% hematocrit),
dispensed into sterile 96-well plates (Corning, USA), and incubated under standard culture conditions
with medium replaced weekly. On day 16, stained thin blood smears were prepared and stained with
Quickdip (POCD) and then examined by microscopy. Parasite-positive cultures were transferred into
50-mm petri dishes (Corning) and then 100-mm petri dishes (Corning) for expansion and cryopreserva-
tion. The parasite-negative wells were checked 1 week later by microscopic analysis of Quickdip-stained
blood smears, and no further parasite-positive wells were identified.
In vitro P. falciparum growth inhibition assays. In vitro inhibition of P. falciparum growth was
assessed using a 72-h isotopic microtest, essentially as previously described (43). Briefly, highly synchro-
nous ring-stage P. falciparum-infected erythrocytes obtained by sorbitol treatment (42) were seeded at
0.5% parasitemia and 2.5% final hematocrit into 96-well tissue culture plates (3596 Costar; Corning, USA)
containing serial dilutions of control or test compounds. Compound vehicle only (0.5% final DMSO) and
the antimalarial drug chloroquine served as negative and positive controls, respectively, in each assay.
After incubating for 48 h under standard P. falciparum culture conditions in RPMI 1640 medium (Gibco,
USA) containing 10% heat-inactivated pooled human sera and 5 g/ml gentamicin (Sigma, USA), 0.5 Ci
[3H]-hypoxanthine (PerkinElmer, USA) was added to each well followed by culturing for a further 24 h.
Cells were harvested onto 1450 MicroBeta filter mats (Wallac, USA), and 3H incorporation was determined
using a 1450 MicroBeta liquid scintillation counter (PerkinElmer). Percentage inhibition of growth for
compound treated versus that for matched vehicle only (0.5% DMSO) controls was determined, and IC50
values were calculated using nonlinear regression analysis in GraphPad Prism. Each compound was
assayed in triplicate wells in at least three independent experiments. Statistical difference between IC50s
was determined using an unpaired t test with GraphPad Prism data analysis software.
In vitro P. falciparum resistance selection. P. falciparum 3D7 clone C3 (3D7-C3)-infected erythro-
cytes were cultured with (and, in parallel, without) PS-3 at 1 IC50 (0.9 M). Parasite growth was
monitored every 1 to 3 days via microscopic examination of Quickdip-stained (POCD, Australia) thin
blood films, with medium changed as needed. When PS-3-treated parasites were observed to be
replicating at a similar rate to that of the untreated controls, compound pressure was gradually increased
in a stepwise manner over several weeks until the parasites were surviving in 10 IC50 concentrations.
At this point, the selected and wild-type clones were assessed in growth inhibition assays to determine
sensitivity for PS-3 and other compounds. Once a resistance phenotype was confirmed, PS-3-selected
and wild-type parasites were subcloned and phenotype assessed again to confirm resistance.
In vitro growth rate analysis of P. falciparum. Highly synchronous ring-stage P. falciparum cultures
starting at 0.25% rings and 2.5% hematocrit were cultured under standard conditions for 72 h.
Quickdip-stained (POCD, Australia) thin blood films were prepared every 24 h, and 3,000 erythrocytes
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were counted by two independent microscopists to determine the mean number of parasites infecting
100 erythrocytes at each time point. Three independent assays were assessed per clone.
Genome sequencing. Genomic DNA was isolated from P. falciparum-infected erythrocytes using a
DNeasy blood and tissue kit (Qiagen, USA). The Nextera XT kit (Illumina) was used to prepare DNA
libraries from samples for whole-genome sequencing using the dual index protocol. The libraries were
run on the Illumina HiSeq 2500 in rapid run mode with 100-bp paired-end reads. The reads were aligned
to the P. falciparum 3D7 reference genome (PlasmoDB v. 13.0) as described previously (44). Single
nucleotide polymorphisms (SNPs) and indels were called with the Genome Analysis Toolkit’s (GATK)
HaplotypeCaller (45, 46). Variants were filtered by quality scores and sequencing bias statistics based on
GATK’s default filtering parameters. SNPs were filtered out if they met any of the following criteria: quality
depth (QD), 2.0; mapping quality (MQ), 50.0, Phred-scaled P value using Fisher’s exact test to detect
strand bias (FS), 60.0; symmetric odds ratio (SOR), 4.0; Z-score from Wilcoxon rank sum test of
alternative versus reference read mapping qualities (MQRankSum), less than 	12.5; ReadPosRankSum
(RPRS) parameter, less than 	8.0. Indels were filtered out if they met any of the following criteria: QD,
2.0; RPRS, less than 	20.0; FS, 200.0. Variants were annotated using snpeff (version 4.2) (47). Custom
scripts were used to compare the variants between the parent sequence and the resistant clones.
CRISPR-Cas9 genome editing. CRISPR/Cas9 editing of mutations in PfPFK9 was performed using a
pDC2-based Cas9 guide RNA (gRNA) plasmid, pDC2-cam-coCas9-U6.2-hDHFR. Two sgRNAs were de-
signed per target site using Benchling (San Francisco, CA). For targeting of L513, gRNA1 (CAATTTATGT
CACATTATCT) and gRNA2 (TCACATTATCTAGGTTATGA) were employed, and for targeting of R860, gRNA3
(CATAACACATTCATAGCACC) and gRNA4 (GGTGCTATGAATGTGTTATG) were used. Donor templates with
656-bp or 750-bp homology to the L513 and R860 target sites, respectively, were synthesized (Thermo
Fisher) and cloned into the AatII-EcoRI sites of the Cas9 vector using Gibson assembly. Plasmids were
transfected by electroporation (0.31 kV, 950 F) into Dd2 parasites and selected with 2.5 nM WR99210 for
8 days before drug pressure was removed. Editing of the recovered parasites was examined by Sanger
sequencing of the bulk culture, and clonal lines were derived by limiting dilution.
Metabolite profiling and stable isotope labeling. Erythrocytes infected with 3D7-C3PS3 clones 1
and 3 and 3D7-C3 were regularly sorbitol synchronized, and trophozoites were separated from unin-
fected erythrocytes using a magnet supplied by Colebrook Bioscience. The enriched infected erythro-
cytes (95% parasitemia) were then allowed to recover for 0.5 to 1 h at 37°C in “complete medium”
(RPMI 1640 supplemented with 0.5% AlbuMAX II, 5% human serum, 20 mM glucose [final concentration],
25 mM HEPES, 100 M hypoxanthine, and 10 g/ml gentamicin).
Stable-isotope incorporation was performed using methods previously described with minor mod-
ifications (48). Briefly, purified infected erythrocytes were resuspended in fresh RPMI 1640 medium at a
cellular density of 1  108 cells/ml and allowed to recover for 10 min. Time courses were initiated by
adding an equal volume of RPMI 1640 containing 11 mM 13C-U-glucose (Sigma), leading to a 1:1 mix of
fully unlabeled/fully labeled glucose. This 1:1 mixing was performed to avoid perturbation of metabolism
during label addition and allows detection of more complex labeling patterns. At predetermined time
points, 1  108 cells were aliquoted, centrifuged (15 s at 14,000  g), washed with 1 ml ice-cold
phosphate-buffered saline (PBS), and centrifuged (15 s at 14,000  g), and metabolites were extracted
with 200 l of 80% acetonitrile (containing 1 M 13C-U-aspartate). Samples were rapidly vortexed and
centrifuged (5 min 14,000  g), and the supernatant was collected.
The metabolites were separated on a SeQuant ZIC-pHILIC column (5 M, 150 mm by 4.6 mm;
Millipore) with a 1260 series high-pressure liquid chromatography (HPLC) system (Agilent) using a
method previously described with modifications (49). Briefly, a flow rate of 0.3 ml/min was used with
20 mM ammonium carbonate in water (A) and 100% acetonitrile (B) as the mobile phase. A binary
gradient was set up as follows: 0.5 min, 80% B; 15.5 min, 50% B; 17.5 min, 20% B; 18.5 min, 5% B; 21 min,
5% B; 23 min, 80% B; held at 80% B until 29.5 min. Detection of metabolites was performed on an Agilent
Q-TOF mass spectrometer 6545 operating in negative electrospray ionization (ESI) mode. The scan range
was 85 to 1,200 m/z between 2 and 27 min at 0.8 spectra/second.
LC-MS .d files were converted to .mzXML files using MS convert and analyzed using MAVEN (50).
Following alignment, metabolites were assigned using exact mass (10 ppm) and retention time
(compared to a standards library of 150 compounds run the same day). Isotopologues for each
metabolite of interest were extracted and integrated, and percent 13C incorporation was converted into
concentration of metabolite labeled using the absolute metabolite concentrations determined previ-
ously (48). When metabolite values were not previously determined (ribose-5-P, sedoheptulose-7-P,
octulose-8-P, and malate), metabolite concentrations were arbitrarily set to 100 M.
The drug-induced changes to the parasite metabolite profile were determined using the experimen-
tal approach described in reference 49. Drug was added at 40 M to cell suspensions (each containing
1  108 cells at 0.4% hematocrit), which were incubated at 37°C under controlled atmospheric conditions
(5% CO2 and 1% O2 in N2). After 2 h of incubation, cell suspensions were processed and metabolites were
extracted for LC-MS analysis as described above.
Isopentenyl pyrophosphate rescue. In vitro isopentenyl pyrophosphate (IPP) pathway rescue
against P. falciparum 3D7 parasites was carried out as previously described (39). Briefly, PS-3 was tested
in P. falciparum in a 72-h [3H]hypoxanthine growth inhibition assay as previously described (43), with the
following modifications. Two identical 72-h assays were performed simultaneously, one supplemented
with 200 M IPP and one without IPP. The antibiotic antimalarial compound clindamycin was used as a
positive control. Three or more independent assays were performed, each in triplicate wells. Each
compound was assayed in triplicate wells in at least three independent experiments. Statistical difference
between IC50s was determined using a two-tailed t test with GraphPad Prism data analysis software.
Fisher et al. ®














































Phosphatase activity of PfHAD1 and PfHAD2. Recombinant enzymes PfHAD1 and PfHAD2 were
expressed and purified fresh as previously described in references 9 and 7, respectively. Phosphate
release was quantified using the EnzChek phosphate assay kit (Invitrogen, Life Technologies) as previ-
ously described (8). In all assays, 200 ng of PfHAD1 and 2,000 ng of PfHAD2 were used and determined
to be within the linear range for assay sensitivity (data not shown). Kinetic parameters for phosphate-
containing substrate AMP (Sigma) were determined from three independent Km curves for each enzyme,
with nonlinear regression analysis performed using GraphPad Prism. The Kms for AMP were determined
to be 4.11  0.88 mM and 4.09  0.55 mM for PfHAD1 and PfHAD2, respectively. Inhibition of phospha-
tase activity for compounds PS-3, PS-3=, and PS-12 was tested across a range of inhibitor concentrations
(200 M to 3 nM) at an ATP concentration of 4 mM. Nonlinear regression was attempted for inhibition
curves using GraphPad Prism; unresolved “ambiguous” fitted curves indicate lack of inhibition up to
200 M under the described assay conditions.
PFK recombinant protein expression. Recombinant proteins PkPFK (762 to 1417 amino acids [aa]),
PkPFK (1 to 663 aa), PfPFK (778 to 1418 aa), and PfPFK (1 to 663 aa) were codon optimized by
Genewiz and cloned between the NdeI and BamHI cloning sites of plasmid BG1861, which introduces an
N-terminal 6His tag. A catalytically dead mutant, PfPFKΔKTIDGD, was also generated utilizing Q5
site-directed mutagenesis (NEB Inc.). Constructs were transformed into the BL21(DE3) Escherichia coli
expression strain (Life Technologies). Cultures were grown to an optical density at 600 nm (OD600) of
0.6 in the presence of ampicillin (100 g/ml) at 37°C shaking at 200 rpm and induced for 2 h with
isopropyl--D-thiogalactoside. Cells were collected by centrifugation and stored at 	80°C. Pellets were
resuspended in sonication lysis buffer containing 10 mM Tris-HCl (pH 7.5), 20 mM imidazole, 1 mM MgCl2,
1 mM dithiothreitol (DTT), 1 mg/ml lysozyme, 100 U Benzonase and cOmplete Mini EDTA-free protease
inhibitor tablets (Roche Applied Science). Proteins were purified via nickel agarose beads (Gold Biotech-
nology) and eluted with 300 mM imidazole, 20 mM Tris-HCl (pH 7.5), and 150 mM NaCl. Eluted proteins
were further purified via size exclusion chromatography using a HiLoad 16/60 Superdex 200 gel filtration
column (GE Healthcare Life Sciences) using an AKTA Explorer 100 fast protein liquid chromatograph
(FPLC) (GE Healthcare Life Sciences). Fast protein liquid chromatography buffer contained 100 mM
Tris-HCl (pH 7.5), 1 mM MgCl2, 1 mM DTT, and 10% (wt/vol) glycerol. Fractions containing purified protein
were pooled, concentrated to 2 mg/ml as determined via Pierce bicinchoninic acid (BCA) protein assay
kit (Thermo Fisher), and flash frozen using liquid nitrogen (LN2) for storage at 	80°C.
PFK recombinant assays. Recombinant PFK activity was measured using a linked enzyme assay as
previously described (5, 7, 51). Briefly, reactions contained 100 mM Tris-HCl (pH 7.5), 1 mM MgCl2, 1 mM
DTT, 10% (wt/vol) glycerol, 0.25 mM NADH, 1 mM ATP, 3 mM fructose 6-phosphate, and excess of linking
enzymes aldolase (7.5 U), triose-phosphate isomerase (3.8 U), and glycerol 3-phosphate dehydrogenase
(3.8 U). Activity in the presence of inhibitors (50 M) was tested for each recombinant protein and
normalized to that for no inhibitor solvent-containing positive controls. Inhibition curves for compounds
PS-3 and PS-12 were determined for PfPFK across the 1:2 dilution series comprising the concentration
range 100 M to 97 nM. Inhibition curves were fitted using nonlinear regression analysis using GraphPad
Prism; unresolved curves indicate minimum IC50 values.
PfPFK model construction. PfPFK subunits were searched against the HHpred server for protein
remote homology detection and three-dimensional (3D) structure prediction using statistics as previ-
ously described (52–55). The Borreliella burgdorferi PFK structure (PDB 1KZH [56]) returned the highest
similarity for both PfPFK domains and was used to predict the 3D structure for each domain using the
program MODELLER. PFK product orientation in the active site of the model was predicted via the
alignment tool, using PyMOL software against the E. coli PFK crystal structure (PDB 1PFK [57]).
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